Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$3.96 -0.8%	$3.69	$3.04 ▼ $8.44	$218.29M	1.16	184,883 shs	124,114 shs
NTLA Intellia Therapeutics	$9.20 -4.2%	$8.30	$5.90 ▼ $28.18	$994.39M	2.14	2.90 million shs	5.90 million shs
NUVB Nuvation Bio	$1.96 +9.2%	$2.15	$1.54 ▼ $3.97	$609.07M	1.37	2.78 million shs	12.71 million shs
PHAR Pharming Group	$10.60 -2.3%	$9.93	$6.65 ▼ $12.61	$737.82M	0.02	6,101 shs	1,340 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	0.00%	+1.01%	+0.25%	+3.37%	-39.08%
NTLA Intellia Therapeutics	0.00%	+14.97%	-0.72%	+6.67%	-61.29%
NUVB Nuvation Bio	0.00%	-1.38%	-17.36%	-5.80%	-38.45%
PHAR Pharming Group	0.00%	-6.48%	+11.51%	+25.67%	+30.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	3.2242 of 5 stars	3.5	4.0	0.0	0.6	3.3	1.3
NTLA Intellia Therapeutics	4.4817 of 5 stars	4.3	1.0	4.7	2.9	2.5	0.6
NUVB Nuvation Bio	3.4224 of 5 stars	4.6	0.0	0.0	2.9	5.0	0.0
PHAR Pharming Group	2.5019 of 5 stars	3.5	3.0	0.0	3.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	3.00	Buy	$8.00	102.02% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	279.89% Upside
NUVB Nuvation Bio	3.20	Buy	$7.17	266.58% Upside
PHAR Pharming Group	3.00	Buy	$30.00	183.02% Upside

Current Analyst Ratings Breakdown

Latest BTMD, NTLA, NUVB, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$197.19M	1.10	$0.76 per share	5.21	($2.78) per share	-1.42
NTLA Intellia Therapeutics	$57.88M	16.46	N/A	N/A	$8.56 per share	1.07
NUVB Nuvation Bio	$7.87M	84.52	N/A	N/A	$1.37 per share	1.43
PHAR Pharming Group	$297.20M	2.43	$0.07 per share	146.30	$3.25 per share	3.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.16M	$0.61	6.49	7.33	N/A	10.93%	-19.44%	20.12%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	353.33	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)

Latest BTMD, NTLA, NUVB, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/7/2025	Q1 2025	BTMD biote	$0.06	$0.08	+$0.02	$0.37	$47.25 million	$48.99 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	1.42	1.14
NTLA Intellia Therapeutics	N/A	4.90	4.90
NUVB Nuvation Bio	N/A	9.01	9.01
PHAR Pharming Group	0.39	2.76	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
NTLA Intellia Therapeutics	88.77%
NUVB Nuvation Bio	61.67%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
NTLA Intellia Therapeutics	3.10%
NUVB Nuvation Bio	29.93%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	54.71 million	41.58 million	Not Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable

BTMD, NTLA, NUVB, and PHAR Headlines

Recent News About These Companies

Pharming Group (NASDAQ:PHAR) Shares Down 3.2% - Here's Why

June 18 at 2:18 PM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's What Happened

June 17 at 12:43 PM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?

June 16, 2025 | marketbeat.com

Short Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%

June 13, 2025 | marketbeat.com

European Penny Stocks Under €200M Market Cap To Watch

June 13, 2025 | uk.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What Happened

June 12, 2025 | marketbeat.com

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

June 11, 2025 | finance.yahoo.com

Pharming Group Announces Key Board Appointments and Approvals at 2025 AGM

June 11, 2025 | tipranks.com

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's Why

June 11, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What Happened

June 10, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Stock Price Up 6.7% - Here's What Happened

June 6, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

June 5, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What Happened

June 4, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Reaches New 1-Year High - What's Next?

June 3, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Large Decline in Short Interest

June 3, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What Happened

May 31, 2025 | marketbeat.com

Pharming Group to participate in June investor conferences

May 28, 2025 | finance.yahoo.com

Pharming Group to participate in June investor conferences | PHARM Stock News

May 28, 2025 | gurufocus.com

Pharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

May 10, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q1 - Results - Earnings Call Presentation

May 9, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD, NTLA, NUVB, and PHAR Company Descriptions

biote NASDAQ:BTMD

$3.96 -0.03 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 +0.00 (+0.13%)

As of 04:11 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Intellia Therapeutics NASDAQ:NTLA

$9.20 -0.40 (-4.17%)

Closing price 04:00 PM Eastern

Extended Trading

$9.22 +0.02 (+0.23%)

As of 07:57 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Nuvation Bio NYSE:NUVB

$1.96 +0.17 (+9.22%)

Closing price 03:59 PM Eastern

Extended Trading

$1.98 +0.02 (+1.02%)

As of 07:59 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharming Group NASDAQ:PHAR

$10.60 -0.25 (-2.30%)

Closing price 03:58 PM Eastern

Extended Trading

$10.60 0.00 (0.00%)

As of 05:16 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time